Summary
Regeneron Pharmaceuticals, Inc. reported strong financial performance for the second quarter and first half of 2016, driven by significant growth in EYLEA net product sales. Total revenues increased year-over-year for both periods, with the first half of 2016 reaching $2.41 billion, up from $1.87 billion in the prior year. Net income also saw a substantial rise, reaching $377.6 million for the first half of 2016, compared to $270.7 million in the same period of 2015. The company's operating expenses increased due to expanded R&D and commercialization activities, including a notable rise in R&D expenses driven by new collaborations and expanded clinical trials. Despite increased spending, the company demonstrated robust top-line growth and improved profitability.
Financial Highlights
44 data points| Revenue | $1.21B |
| Cost of Revenue | $41.25M |
| Gross Profit | $1.17B |
| R&D Expenses | $559.93M |
| SG&A Expenses | $292.04M |
| Operating Expenses | $921.00M |
| Operating Income | $291.63M |
| Net Income | $196.22M |
| EPS (Basic) | $1.88 |
| EPS (Diluted) | $1.69 |
| Shares Outstanding (Basic) | 104.63M |
| Shares Outstanding (Diluted) | 116.23M |
Key Highlights
- 1Total revenues for the first half of 2016 increased by 29% to $2.41 billion, up from $1.87 billion in the first half of 2015.
- 2Net income for the first half of 2016 grew by 40% to $377.6 million, or $3.24 per diluted share, compared to $270.7 million, or $2.35 per diluted share, in the first half of 2015.
- 3EYLEA net product sales in the U.S. for the first half of 2016 increased by 35% to $1.61 billion, reflecting strong sales volume growth.
- 4Sanofi collaboration revenue saw a modest increase for the first half of 2016 to $383.1 million, primarily driven by the immuno-oncology collaboration.
- 5Bayer collaboration revenue significantly increased by 44% to $371.5 million for the first half of 2016, mainly due to higher net profit from EYLEA sales outside the U.S.
- 6Research and Development expenses increased by 40% to $1.03 billion for the first half of 2016, reflecting investments in new collaborations (e.g., Intellia) and ongoing clinical programs.
- 7Selling, general, and administrative expenses increased by 46% to $581.7 million for the first half of 2016, driven by increased commercialization activities and higher headcount.